8 results about "Apoptosis" patented technology

The invention discloses an improved culture medium for neonatal pig islet cells and a use method of the same. An apoptosis inhibitor Z-VAD-FMK, a human basic fibroblast growth factor hFGF-beta, a vascular endothelial growth factor VEGF, an insulin-like growth factor R3-IGF-1, a human epidermal growth factor hEGF, a hepatocyte growth factor hHGF, pig serum, sodium selenite, insulin, transferrin, ethanol amine, 1-methyl 3-isobutyl xanthine, nicotine, cortisol, penicillin and streptomycin are added in HAM'S F10 culture medium. According to the culture medium, apoptosis can be reduced and recovery rate can be increased; the cultured cells have a sensitive glucose stimulation response and more mature functions compared with generally-cultured islet cells; the insulin secretion amount of the islet cells with the same quantity is increased; the viability of islet beta-cells is improved; the breakages of islet cell clusters are reduced, and the envelops of the cell clusters are complete, so that the cell clusters are more suitable for being transplanted.

The invention discloses a polypeptide for inhibiting cell proliferation and inducing apoptosis and a preparation method and use thereof. The polypeptide disclosed by the invention comprises a polypeptide sequence 'SPHSG', namely YGRKKRRQRRR-GYLSKVRGISEVL, or another polypeptide sequence 'MRSP', which is similar to the polypeptide sequence in homology and function, namely YGRKKRRQRRR-DVKGYLSKVRGISEVL. An experimental basis is provided for application of the polypeptide in a coated balloon or a coated bracket. Compared with the traditional coated drug, the polypeptide does not have toxic or side effects and immunogenicity of chemical drugs as a small segment of Mfn2. The practicability is also superior to rapamycin. Therefore, the polypeptide has a wide application prospect and great clinical application value.

The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.

Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

The invention relates to usage of 3-carbonyl-12-alkene-ursane compound for inhibiting gastric cancer cell SGC-7901 and hepatoma cancer cell BEL-7404. Experiment shows that the 3-carbonyl-12-alkene-ursane compound is effective to inhibit cell proliferation of the gastric cancer cell SGC-7901 and the hepatoma cancer cell BEL-7404 and can be used for preparing antitumor medicine. Electrophoretic detection shows that the 3-carbonyl-12-alkene-ursane compound can accelerate apoptosis of the hepatoma cancer cell BEL-7404 by accelerating increase of apoptosis relative gene Bax expression.

The invention belongs to the field of chemical medicine, particularly relates to application of pseudostrychnine to inhibiting human colon cancer cells and aims at providing new application of the pseudostrychnine to inhibiting the human colon cancer cells. The human colon cancer cells are HT-29 cells; the pseudostrychnine can inhibit propagation of the HT-29 cells and promote apoptosis of the HT-29 cells, and the apoptosis rate is in positive correlation with the concentration of the pseudostrychnine; the applied concentration of the pseudostrychnine is 125-1000 mu M. The application of the pseudostrychnine to the inhibiting human colon cancer cells provides a new way for treating human colon cancer and has an important development and application prospect in antitumor drugs.

The invention discloses an application of GSK1838705a in ALK + ALCL and crizotinib-resistant ALK + ALCL. GSK1838705a is used for treating tumors, GSK1838705a is used for treating ALK + ALCL, and GSK1838705a is used for treating ALK + ALCL of crizotinib-resistant patients. GSK1838705a can inhibit the proliferation of ALK + ALCL cell line and crizotinib-resistant ALK + ALCL cell line, and induces the apoptosis of the cell line. Compared with the blank control group, GSK1838705a significantly inhibits the expression of p-IGF, p-ALK, p-AKT, p-STATT3 in the ALK + ALCL cell line and the crizotinib-resistant ALK + ALCL cell line, and the expression of activated apoptosis-related proteins is increased significantly. GSK1838705a significantly inhibits the growth of transplanted tumors in mice, andimproves the survival time of transplanted tumor mice, so that GSK1838705a shows anti-tumor effects in the in vivo and in vitro experiments, and a new use for ALK + ALCL and crizotinib-resistant ALK +ALCL is provided.

The invention provides a method for building stable overexpression MGST1 gene cells and primarily studying the biological characteristics of the cells. The method comprises the following steps of (1)synthesizing human MGST1 target gene segments through PCR; (2) connecting the MGST1 target gene segments with eukaryotic plasmid pcDNA3 to form eukaryotic recombinant plasmids; converting the eukaryotic recombinant plasmids into sensory bacterial cells to be cultured; and then selecting monoclone for performing PCR amplification gel electrophoresis to screen out positive clone; (3) extracting thepositive clone screened out from the step (2); analyzing the built eukaryotic recombinant plasmids by using a restriction enzyme double digestion atlas; and performing DNA sequence analysis; and (4) transfecting SPC-A-1 human lung adenocarcinoma cells by the recombinant plasmids pcDNA3-MGST1 with the correct sequence obtained in the step (3); screening SPC-A-1 cells for stably overexpressing MGST1by using G418; and observing the biological characteristics of the cells for stably overexpressing MGST1. The result shows that through the stable overexpression of the MGST1, the cell proliferationcan be promoted; the cell apoptosis can be inhibited; and the cell clone formation capability can be enhanced.